Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle by Arechavala-Gomeza, V. et al.
798
HUMAN GENE THERAPY 18:798–810 (September 2007)
© Mary Ann Liebert, Inc.
DOI: 10.1089/hum.2006.061
Comparative Analysis of Antisense Oligonucleotide Sequences
for Targeted Skipping of Exon 51 During Dystrophin 
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ABSTRACT
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene that result in the ab-
sence of functional protein. In the majority of cases these are out-of-frame deletions that disrupt the reading
frame. Several attempts have been made to restore the dystrophin mRNA reading frame by modulation of
pre-mRNA splicing with antisense oligonucleotides (AOs), demonstrating success in cultured cells, muscle ex-
plants, and animal models. We are preparing for a phase I/IIa clinical trial aimed at assessing the safety and
effect of locally administered AOs designed to inhibit inclusion of exon 51 into the mature mRNA by the splic-
ing machinery, a process known as exon skipping. Here, we describe a series of systematic experiments to val-
idate the sequence and chemistry of the exon 51 AO reagent selected to go forward into the clinical trial
planned in the United Kingdom. Eight specific AO sequences targeting exon 51 were tested in two different
chemical forms and in three different preclinical models: cultured human muscle cells and explants (wild type
and DMD), and local in vivo administration in transgenic mice harboring the entire human DMD locus. Data
have been validated independently in the different model systems used, and the studies describe a rational
collaborative path for the preclinical selection of AOs for evaluation in future clinical trials.
INTRODUCTION
DUCHENNE MUSCULAR DYSTOPHY (DMD) is caused by non-sense or frame-shifting mutations in the DMD gene, which
results in nonfunctional dystrophin proteins (Hoffman et al.,
1987). At the same time, interstitial mutations at the DMD lo-
cus that maintain the dystrophin mRNA open reading frame
give rise to internally deleted but semifunctional dystrophins
and the milder Becker muscular dystrophy (BMD) (Hoffman et
al., 1987; Monaco et al., 1988). Internally truncated but at least
partially functional dystrophins are also expressed in so-called
revertant fibers, individual dystrophin-positive fibers found in
50% of DMD patients and in mdx mice (Nicholson et al., 1989;
Hoffman et al., 1990; Burrow et al., 1991; Fanin et al., 1992;
Sherratt et al., 1993; Yokota et al., 2006). Revertant fibers arise
via some alternative splicing mechanism occurring within dys-
trophin pre-mRNAs, skipping of frame-shifting exons to re-
move protein-truncating mutations, and restoration of the dys-
trophin open reading frame (Lu et al., 2000). These revertant
dystrophins lack exon domains flanking the gene lesion in DMD
patients (Fanin et al., 1995; Thanh et al., 1995) and the mu-
tated exon 23 in the mdx mouse (Lu et al., 2000). Despite be-
ing internally truncated, dystrophin molecules found in BMD
patients can be functional, as demonstrated by several families
with in-frame deletions in the DMD gene, associated with ele-
vated serum creatine kinase but displaying no clinical myopa-
thy (e.g., deletions of exons 32–44, 48–51, or 48–53 [Melis et
al., 1998], exon 48 [Morrone et al., 1997], exons 48–51 or
50–53 [Beggs et al., 1991], exons 45–55 [Beroud et al., 2007],
or exons 50–51 [Lesca et al., 2007]). The efficacy of internally
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truncated dystrophins lacking an appreciable portion of the rod
domain has also been demonstrated in transgenic mdx mice, and
exploited to design so-called microdystrophins compatible with
delivery by AAV vectors. These engineered recombinant mi-
crodystrophins have been shown to restore normal expression
of the dystrophin-associated protein complex (DPC), improve
sarcolemmal stability, and prevent myofiber degeneration in the
mdx mouse model (Wang et al., 2000; Fabb et al., 2002; Harper
et al., 2002; Gregorevic et al., 2006).
The first suggestion that a functional, truncated dystrophin
molecule could be created in DMD patients originally came
from Takeshima et al. after skipping exon 19 in vitro in con-
trol cells (Takeshima et al., 1995; Pramono et al., 1996). Shortly
after, restoration of the reading frame in dystrophic cells was
shown by Dunckley et al. (1998). These authors, and others im-
mediately afterward, proposed the use of antisense oligonu-
cleotides to modulate dystrophin mRNA splicing to enlarge out-
of-frame DMD mutations into the nearest in-frame BMD-like
mutation and produce an internally deleted functional dys-
trophin protein (Dunckley et al., 1998; Wilton et al., 1999;
Takeshima et al., 2001; van Deutekom et al., 2001).
The mechanism of antisense oligonucleotide (AO) modula-
tion of dystrophin pre-mRNA splicing involves hybridization
to specific motifs involved in splicing and exon recognition in
the pre-mRNA. This prevents normal spliceosome assembly
and results in the failure of the splicing machinery to recognize
and include the target exon(s) in the mature gene transcript
(Mann et al., 2001; Aartsma-Rus et al., 2003).
In this way one or more exons and their flanking introns are
removed during splicing of the pre-mRNA. In the case of the
dystrophin gene deletions, selective removal of specific flank-
ing exons should result in in-frame mRNA transcripts that may
be translated into an internally deleted, BMD-like and func-
tionally active dystrophin protein with predictable therapeutic
activity (Wilton et al., 1999; van Deutekom et al., 2001).
In DMD research, the potential clinical use of AOs has evolved
from studies in vitro on cultured mdx mouse muscle cells (Dunck-
ley et al., 1998; Mann et al., 2001, 2002) and human DMD mus-
cle cells (van Deutekom et al., 2001; Aartsma-Rus et al., 2002,
2003, 2004a) to in vivo studies in mdx and GRMD (golden re-
triever muscular dystrophy) animal models (Lu et al., 2003, 2005;
Fletcher et al., 2006; McClorey et al., 2006b) (Table 1). Direct
in vivo AO-induced exon skipping in humans, however, has yet
to be demonstrated and this proof of principle, along with clini-
cal safety, is the crucial aspect of initial clinical studies. Prepa-
ration has been reported for two parallel clinical trials of AO
therapeutics in DMD patients that will target dystrophin exon 
51. Exclusion of exon 51 is predicted to allow the restoration of
the dystrophin open reading frame (ORF) in 17% of DMD
deletion patients (deletions of exons 45–50, 47–50, 48–50, 49
and 50, 50, 52, and 52–63; van Deutekom and van Ommen,
2003). Although these two clinical trials will both target exon 51,
each will evaluate different AO chemistries: 2-O-methyl-modi-
fied ribose moieties on a phosphorothioate backbone (2-OMe
AOs) (completed by Leiden University Medical Center [LUMC]
and Prosensa [Leiden, The Netherlands] [van Deutekom et al.,
2007]) and phosphorodiamidate morpholino oligomers (PMOs)
(http://clinicaltrials.gov/ct/show/NCT00159250; in progress in
the United Kingdom [Muntoni et al., 2005]).
The majority of the AO work undertaken on cultured cells
has been performed with 2-OMe AOs, as this chemistry is read-
ily available and, more importantly, allows efficient cell trans-
fection as a cationic lipoplex preparation (Summerton and
Weller, 1997; Fletcher et al., 2006). Although PMOs appear to
be more efficient after direct administration to tissues in the
mdx mouse than the equivalent 2-OMe AO (Fletcher et al.,
2006), their poor uptake in vitro limits the approaches that can
be used to refine AO design.
In this study, we have compared, in a blinded fashion, eight
different sequences targeting dystrophin exon 51. The two most
efficient sequences were finally compared in their PMO version.
Dose–response experiments were used to evaluate the lowest
concentration capable of inducing skipping and time course ex-
periments were performed to study the persistence of the exon
skipping after transfection. All preliminary experiments were
undertaken in normal human skeletal muscle cells (hSkMCs) be-
cause these cells are more readily available than patient-derived
cell lines. All the key experiments were repeated on the cells of
DMD patients with different but relevant deletions. As a proof
of principle, the AOs were also tested on muscle explants from
DMD patients to study their effect in an ex vivo structure, as
such explants have been described as a putative model in which
to test gene therapy models (Fletcher et al., 2006; McClorey et
al., 2006a). These experiments were complemented by the in-
tramuscular administration of PMO versions of the two most
promising sequences into the gastrocnemius muscle of a mouse
model transgenic for the entire human dystrophin locus (Brem-
mer-Bout et al., 2004). All these approaches suggested that one
of the AOs (AO B30, 6695) more robustly induced exon
skipping, and this sequence has now been chosen for the phase
I/IIa trial which is underway in the United Kingdom.
MATERIALS AND METHODS
AO design
Eight different 2-O-methyl AOs to human dystrophin exon
51 (A20, B30, and C20–H20) were designed on the basis of ES-
Efinder analysis (Smith et al., 2006), and relative to previously
published sequences (Fig. 1A). Splice site AOs (C20 to H20)
were designed on the basis of work performed in our laboratory
on the mdx mouse, published previously (Graham et al., 2004).
To avoid differences in synthesis conditions and concentrations
all AOs were purchased from Eurogentec (Seraing, Belgium), di-
luted to the same concentration in water by the same operator,
aliquoted, and stored at 80°C. Three further AOs (A25, B30,
and I25; Fig. 1A) were synthesized as phosphorodiamidate mor-
pholino oligomers (PMOs) by Gene Tools (Philomath, OR). To
facilitate introduction into cultured cells, the uncharged PMOs
were hybridized to phosphorothioate-capped DNA leashes, based
on a previous design (Gebski et al., 2003), and stored at 4°C.
Cell culture and AO transfection
Transfections of AOs were performed at two separate institu-
tions, Imperial College (IC, London, UK) and Royal Holloway
(RH, London, UK), using normal primary human skeletal mus-
cle cells from different sources: human fetal muscle cells were
obtained from the Medical Research Council (MRC) Tissue Bank
(London, UK) and human primary skeletal muscle cultures were
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obtained from muscle biopsies obtained at the Dubowitz Neuro-
muscular Unit, Hammersmith Hospital (London, UK), both with
the approval of the institutional ethics committee, and using
slightly different protocols. The comparable results obtained in
this way reinforce the findings presented here. Myoblasts were
seeded on Matrigel (0.1 mg/ml)-precoated 6-well plates, cultured
in differentiation medium (Dulbecco’s modified Eagle’s medium
[DMEM] plus 5% horse serum) (IC), or in supplemented mus-
cle cell differentiation medium (Promocell, Heidelberg, Ger-
many) (RH), and transfected when myoblasts fused to form vis-
ible myotubes (elongated cells containing multiple nuclei and
myofibrils), usually after 2 days. Transfection reagent Lipofectin
(Invitrogen, Paisley, UK) was added to the AOs at a ratio of 2
l of Lipofectin to 1 g of 2-OMe AO, or 4 l of Lipofectin
to 1 g of PMO, optimized previously (data not shown), and my-
otube cultures were incubated with the mixture for 4–5 hr, ac-
cording to the manufacturer’s instructions. AO concentrations
ranging from 50 to 500 nM were used for experiments exploring
dose–response correlations, whereas time course experiments
were undertaken at concentrations of 100 and 300 nM.
Explants
Muscle was cut into fragments approximately 2–3 mm3 in
size and transferred to a 24-well plate containing a 400 nM con-
centration of the AOs diluted in a final volume of 500 l of
OptiMEM (Invitrogen) plus penicillin (100 units/ml) and strep-
tomycin (0.1 mg/ml). Forty-eight hours after the infusion, 500
l of DMEM plus 10% horse serum was added to each well.
RNA was isolated 7 days after the infusion.
RNA isolation and reverse transcription-polymerase
chain reaction analysis
Again, slightly different methods were employed in the dif-
ferent institutions for RNA isolation and reverse transcription-
polymerase chain reaction (RT-PCR) analysis, thereby con-
firming the validity of the results obtained. Twenty-four hours
after transfection (or later in time course experiments), RNA was
extracted with TRIzol (Invitrogen) (IC), or with the RNeasy sys-
tem (Qiagen, Crawley, UK) (RH). Aliquots of 400 ng of total
RNA were used for RT-PCR analysis (55°C for 35 min) in a
20-l reaction using Transcriptor reverse transcriptase (Roche)
(IC) and a specific primer (primer sequences available on re-
quest). Three microliters of this reaction was used as a template
for a primary PCR consisting of 20 cycles of 94°C (40 sec),
60°C (40 sec), and 72°C (80 sec), using specific primers de-
pending on the deletions present in the cells. From this reaction
1.5 l was later used as a template for a nested PCR, consist-
ing of 30 cycles of 94°C (40 sec), 60°C (40 sec), and 72°C (80
sec). Alternatively (RH), RNA was subjected to single-tube RT-
PCR using a GeneScript system (Genesys, Camberley, UK).
PCR products were analyzed on 1.5% agarose gels in Tris-ac-
etate/EDTA buffer. Skipping efficiencies were determined by
quantification of the PCR products at the Center for Human and
Clinical Genetics (Leiden University Clinical Center, Leiden,
The Netherlands), using a DNA 100 LabChip kit and an Agi-
lent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA).
Sequence analysis
RT-PCR products were excised from agarose gels and ex-
tracted with a QIAquick gel extraction kit (Qiagen). Direct
DNA sequencing was carried out by the MRC Genomics Core
Facility.
Western blot analysis of dystrophin protein
Cells were cultured and transfected as described above. One
week after transfection, cells were harvested (four wells per
sample) and washed with phosphate-buffered saline (PBS) and
protein extracts were isolated directly in 50 l of loading buffer
(75 mM Tris-HCl [pH 6.8], 15% sodium dodecyl sulfate [SDS],
5% 2-mercaptoethanol, 2% glycerol, bromophenol blue, and
protease inhibitors). Samples were denatured at 95°C for 5 min
and centrifuged at 18,000  g for 5 min before being loaded in
a 6% polyacrylamide gel with a 4% stacking gel. Gels were
electrophoresed for 4 hr at 100 V and blotted to a nitrocellu-
lose membrane overnight at 200 mA. Blots were blocked for 1
hr with 10% nonfat milk in PBS–Tween (PBST) buffer and
ARECHAVALA-GOMEZA ET AL.802
FIG. 1. (A) Sequences and localization of the various antisense oligonucleotides (AOs) compared in this project. AOs A25 and
I25 were phosphorodiamidate morpholino oligomers (PMOs), whereas B30 corresponds to the sequences of both the 2-O-methyl
(2-OMe) version and the PMO. All remaining sequences were compared as 2-OMe AOs. (B) Eight different 2-OMe AOs were
compared in a blinded fashion to evaluate their capacity to produce correct exon skipping in normal human skeletal muscle cells
(hSkMCs). Once the code was revealed, the two most successful AOs (lanes 1 and 8) were studied in terms of dose and time
course. Lane 1, AO A20; lane 8, AO B30.
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dystrophin protein was detected by probing the membrane with
NCL-DYS1 primary antibody (Vision BioSystems, Newcastle
upon Tyne, UK) diluted 1:40 in 3% milk. A biotinylated sec-
ondary anti-mouse IgG antibody (diluted 1:1000; GE Health-
care, Little Chalfont, UK) and a streptavidin/horseradish per-
oxidase (HRP)-conjugated antibody (diluted 1:5000; Dako,
Carpinteria, CA) allowed visualization in a luminol–HRP
chemiluminescence reaction (ECL-Plus; GE Healthcare) on
film (Hyperfilm; GE Healthcare) exposed at 20-sec intervals
(20 sec to 2 min, with occasional longer exposures).
Transgenic human DMD mice
Work with transgenic human (h)DMD mice was performed
at the LUMC, where a transgenic mouse expressing a complete
copy of the human DMD gene was generated (Bremmer-Bout
et al., 2004). The experiments were authorized by the Animal
Experimental Commission (UDEC) of the Medical Faculty of
Leiden University. Mice (approximately 5 weeks of age) were
anesthetized by intraperitoneal injection of a 1:1 (v/v) solution
of Hypnorm (fentanyl and fluanisone; Janssen Pharmaceutica,
Berchem, Belgium) and Dormicum (midazolam; Roche, Mij-
drecht, The Netherlands). The muscles were pretreated to in-
duce muscle degeneration and regeneration by injection of 3.6
l of polyethylenimine (PEI) in 5% (v/w) glucose on days 1
and 2. A total of 2.9 nmol of each PMO per injection in a fi-
nal volume of 40 l was injected intramuscularly in both gas-
trocnemius muscles, using a Hamilton syringe with a 22-gauge
needle. Mice received two injections at 24-hr intervals and were
then killed. This muscle was isolated and frozen in liquid ni-
trogen-cooled 2-methylbutane (Bremmer-Bout et al., 2004).
RESULTS
Exon-internal 2-OMe AOs are more efficient than
those targeting the 5 splice site
AO sequences targeting exon 51 were designed using dif-
ferent strategies. One strategy, based on previous results ob-
tained in mouse dystrophin exon 23 (Graham et al., 2004), was
that of designing an overlapping stepped array of 2-OMe AOs
complementary to the 5 (donor) splice site of intron 51. The
other strategies examined other potential splice motifs across
exon 51, including the 3 (acceptor) splice site and the branch
point, as well as exon-internal sequences (Aartsma-Rus et al.,
2004b; Wilton et al., 2007). After initial characterization in
each partner laboratory (Table 2) (Aartsma-Rus et al., 2002,
2005; Harding et al., 2007), eight AOs, six targeting the 5
splice site designed in the first partner laboratory (RH) (C20
to H20; Fig. 1A) plus two overlapping AOs (A20 and B30;
Fig. 1A), designed independently in the other two partner lab-
oratories (LUMC and the University of Western Australia
[UWA], Perth, Australia), were then all compared in parallel
in a fourth laboratory (IC), at a concentration of 100 nM on
cultured differentiated human skeletal muscle cells. RNA from
these cultures was analyzed blindly by RT-PCR, the results of
which are shown in Fig. 1B. Whereas the AOs targeting the
5 splice site (C20 to H20; Fig. 1A) were confirmed, surpris-
ingly, as being largely ineffective at inducing skipping of exon
51 (Fig. 1B, lanes 2 to 7), those against the exon-internal
sequences, AOs A20 and B30 (Fig. 1A), were capable of in-
ducing exon 51 skipping at a level approaching 50% (Fig. 1B,
lanes 1 and 8).
TABLE 2. PRELIMINARY COMPARISON BETWEEN CANDIDATE ANTISENSE OLIGONUCLEOTIDESa
Compared
in this
Institution AO name Sequence study Chemistry
Leiden h51AON1 UCAAGGAAGAUGGCAUUUCU A20 2OMe
University h51AON24 GAAAGCCAGUCGGUAAGUUC
Medical Center, h51AON27 CACCCACCAUCACCC
The h51AON2e CCUCUGUGAUUUAUAACUUGAU
Netherlands h51AON29 UGAUAUCCUCAAGGUCACCC
University of H51A (0125) ACCAGAGUAACAGUCUGAGUAGGAGC
Western H51A (6190) ACAUCAAGGAAGAUGGCAUUUCUAGUUUGG
Australia, H51A (6690) ACAUCAAGGAAGAUGGCAUUUCUAG
Australia H51A (6895) CUCCAACAUCAAGGAAGAUGGCAUUUCUAG B30 2OMe/PMO
H51A (111134) UUCUGUCCAAGCCCGGUUGAAAUC
H51A (175195) CACCCACCAUCACCCUCUGUG
H51A (199220) AUCAUCUCGUUGAUAUCCUCAA
H51A (0817) AUCAUUUUUUCUCAUACCUUCUGCU
H51A (1607) CUCAUACCUUCUGCUUGAUGAUC
Royal Holloway DMD51 (128) UAGUUCGUCUUCCAUACUCU C20 2OMe
University of DMD51 (911) UUCGUCUUCCAUACUCUUUU D20 2OMe
London, United DMD51 (614) GUCUUCCAUACUCUUUUUUA E20 2OMe
Kingdom DMD51 (317) UUCCAUACUCUUUUUCUA F20 2OMe
DMD51 (120) CAUACUCUUUUUUACUAUUU G20 2OMe
DMD51 (423) ACUCUUUUUUACUAUUUUCA H20 2OMe
DMD51 (718) CGTCTTCCATACTCTTTTTTACTAT I25 PMO
DMD51 (6387) TTTGATCTTTACGGTAGAAGGAACT A25 PMO
aUndertaken in the partner laboratories (Leiden University Medical Center, Leiden, The Netherlands: University of Western
Australia, Perth, Australia; Royal Holloway-University of London, Egham, UK) (Aartsma-Rus et al., 2004b; Harding et al, 2007)
and a selection was further confirmed in a fourth laboratory (Imperial College, London, UK).
Exon-internal 2-OMe AOs induce efficient and
persistent exon 51 skipping
The two most efficient AOs (A20 and B30) were compared
in terms of dose response in normal human skeletal muscle
cells, to determine the concentration necessary to induce exon
skipping, and in a time course study, to determine how long af-
ter transfection the effect lasted in culture. AO concentrations
ranging from 50 to 400 nM were used, and the results shown
in Fig. 2A demonstrate that skipping of exon 51 was achieved
at the lowest dose used for both AOs, as judged by the size dif-
ference (212 bp) between the skipped and full-length bands.
Precise exon 51 skipping was confirmed by direct sequencing
of the lower band (Fig. 2C). Transfection of AOs A20 and B30
into normal human skeletal muscle cultures at concentrations
of 100 and 300 nM, followed by harvesting of RNA at various
time points, demonstrated that skipped products were still de-
tectable by RT-PCR 10 days after transfection (Fig. 2B).
The same experiments were repeated in differentiated mus-
cle cultures derived from DMD patients carrying deletions,
which could be amenable to exon 51 skipping to restore the read-
ing frame. Two patients carrying different deletions (48–50
and 50) were used for these experiments. Cultured myogenic
cells from the DMD patient with a deletion of exons 48 to 50
were used to perform a dose–response study of the two 2-OMe
AOs. This demonstrated that, whereas both AOs were able to
induce exon skipping at doses as low as 50 nM, AO B30 was
much more efficient at inducing exon 51 skipping, even at low
concentrations, as can be appreciated by the relative intensities
of the full and the skipped bands (Fig. 3A). Direct sequencing
of the lower RT-PCR product showed an accurate junction be-
tween exons 47 and 52 (Fig. 3B), confirming exon 51 skipping.
Furthermore, protein samples isolated from similarly trans-
fected cultures from this patient were analyzed by Western blot-
ting, and demonstrated the restoration of dystrophin protein at
levels that correlate with the relative degree of exon skipping
observed by RT-PCR (compare lanes A20 and B30; Fig. 3C).
The levels of dystrophin are, however, rather low, as compared
with an equivalent loading of protein extract from normal hu-
man cells (Fig. 3C, lane C). No dystrophin is detectable in a
protein extract of nontransfected cells from this patient (Fig.
3C, lane Mock).
Cells derived from the DMD patient with a deletion of exon
50 were used to study the persistence of the skip over time. At
concentrations of 100 nM, it was evident that AO B30 (6695)
was substantially more effective at inducing the skipping of exon
51 for as long as 9 days after transfection (Fig. 3D).
Exon skipping in response to low doses of PMO in
human fetal muscle cells and DMD cells
The PMO backbone presents certain advantages for uptake
by skeletal muscle after systemic injection in vivo (Sazani et
al., 2002) but its uptake in vitro is relatively poor unless ei-
ther high concentrations are used, or scrape loading is em-
ployed to enhance cellular uptake (Summerton and Weller,
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FIG. 2. (A) Normal hSkMCs were trans-
fected with increasing concentrations of the
two 2-OMe AOs. Both AOs achieved the
correct skip at low concentrations, with AO
B30 (6695), showing more consistent
results. (B) Normal hSkMCs were trans-
fected with two concentrations (100 and
300 nM) of the two AOs and studied 1, 3,
7, and 10 days after transfection. It was pos-
sible to confirm the presence of a fragment
of the expected size 10 days after transfec-
tion in each case. (C) The bands were an-
alyzed by sequencing, confirming that the
correct exon skip had been achieved. In
both experiments, whereas the skip
achieved with AO A20 was approximately
40% of the total, the skipped band present
when cells were transfected with AO B30
was approximately 60%. Note that addi-
tional fragments, slightly shorter than the
wild-type products, are visible in some
analyses. This is due to heteroduplex for-
mation and has been described previously
(Aartsma-Rus et al., 2003).
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1997). However, we have used the observations of Gebski et
al. (2003) to design mixed backbone DNA leashes, which can
complex with transfection reagents and thus act as carriers for
PMOs into cultured cells. We tested four different, commer-
cially available transfection reagents for their ability to intro-
duce a leashed PMO variant of AO B30 into normal human
skeletal muscle cells in culture, at a relatively high concentra-
tion of 500 nM. Although all of the reagents tested were ca-
pable of achieving a degree of transfection, as judged by the
presence of exon 51 skipping in the usual RT-PCR assay (Fig.
4), it was evident that the use of Lipofectin (Invitrogen), at a
ratio of 4 l/g of leashed PMO, was the most effective in
these cultures. Other ratios of Lipofectin were also tested but
found to be less effective (data not shown). We subsequently
used these conditions to directly compare three PMOs in nor-
mal human skeletal muscle cells (B30, A25, and I25; Fig. 1A)
in two of the research laboratories (IC and RH). I25 was in-
cluded, despite the fact that the 2-OMe tested had not been ef-
fective at achieving exon skipping when targeting the 5 splice
site, because it targeted the 5 splice site, which was shown
previously to be effective in mouse exon 23 (Mann et al., 2002;
Graham et al., 2004). In addition, when these experiments were
designed it was not clear whether one could extrapolate results
between sequences when different chemistries were used. The
leashed B30 PMO was clearly the most efficient, demonstrat-
ing efficacy at the lowest concentration tested in both labora-
tories (50 nM) (Fig. 5A and B): A25 showed less efficient re-
sults than B30 at IC (Fig 5A), whereas at RH, the two leashed
25-mer PMOs (A25 and I25) appeared incapable of inducing
skipping of exon 51 to any substantial level at either 100 or
500 nM (Fig. 5B). The leashed PMOs A25 and B30 were also
transfected at IC into cells from the DMD patient with a dele-
FIG. 3. (A) Cells from a DMD patient with a deletion in exons 48 to 50 were transfected with increasing concentrations of the
two 2-OMe AOs and analyzed 9 days after transfection. Cells transfected with AO B30 showed exon skip (50–70%), even at a
low dose (50 nM), whereas the skip achieved with AO A20 was less efficient. (B) The lower bands were analyzed by sequenc-
ing, confirming that the correct exon skip had been achieved. (C) Western blot probed with dystrophin and loading control stained
with Protogold (BBInternational, Cardiff, UK). Normal muscle protein extract (30 g) was used as a full-length dystrophin con-
trol (C). Mock-transfected DMD myoblasts acted as a negative control (Mock). Bands of the correct size can be appreciated in
the lysates of all treated cells (A20 and B30) but not in the untreated cells. (D) Cells from a DMD patient with a deletion in exon
50 were transfected with a 100 nM concentration of the two AOs and studied 1, 3, 6, and 9 days after transfection. It was pos-
sible to confirm the presence of a fragment of the expected size 9 days after transfection of both AOs, but the percentage of the
skip was 13% for AO A20 and 73% for AO B30.
tion of exon 50, demonstrating skipping by RT-PCR (Fig. 5C)
and de novo production of dystrophin protein at low levels (Fig.
5C and D).
AO B30 is able to induce exon 51 skipping in DMD
muscle explants
Once results had been confirmed in cultured cells from DMD
patients, we wished to determine whether muscle fragments re-
taining some of their original three-dimensional properties
would be able to produce the same exon skipping when AOs
were applied. We tested the PMO B30 on several muscle ex-
plants derived from a DMD patient with a nonrelevant deletion
(3–11), as a proof of principle. The correct-sized RT-PCR
product was observed, consistent with accurate exon 51 skip-
ping (Fig. 6A, lane AO B30), which was subsequently con-
firmed by direct sequencing of the RT-PCR product (Fig. 6B).
Blind comparison of several AOs in the hDMD mouse
The hDMD mouse offers the possibility of studying process-
ing of the human DMD gene in an in vivo setting, providing a
model to test the behavior of the AO reagents in vivo before
clinical testing in patients. PMOs A25, B30, and I25 were in-
jected into the gastrocnemius muscle of hDMD mice, and RNA
extracts from treated muscles were analyzed, in a blinded fash-
ion, 2 weeks later for exon 51 skipping. The hierarchy of effi-
cacy of PMOs was the same as that demonstrated in vitro, with
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FIG. 4. Optimization experiments to select an adequate transfection reagent with leashed PMOs in in vitro experiments. AO
B30 was tested in combination with four different transfection reagents at a fixed concentration of 500 nM.
FIG. 5. (A) HFM cells were transfected
at Imperial College (IC) with increasing
concentrations of the PMO AOs A25 and
B30. Both AOs achieved the correct skip at
low concentrations. AO A25 had a skipping
efficiency between 10 and 20% and AO
B30, between 40 and 50%. (B) In a sepa-
rate experiment at Royal Holloway (RH),
PMO AOs A25 and B30 were compared
with a PMO targeting the 5 splicing site
(I25) on normal hSkMCs. Only AO B30
was able to produce the correct skip. (C)
PMO AO B30 was also tested on Duchenne
muscular dystrophy (DMD) myotubes con-
taining an exon 51 skippable deletion and
the correct skip was achieved even at the
lower concentrations. (D) Western blot
analysis of cell lysates of DMD cells (50)
treated with the two PMOs shows the pres-
ence of dystrophin protein in this in vitro
experiment.
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the highest percentage of skipping being achieved with PMO
B30, 6695 (Fig. 7, lane 4).
DISCUSSION
DMD is a fatal neuromuscular disorder that affects 1 in 3500
male newborn boys (Moser, 1984). There is no cure for DMD,
but a putative treatment may lie in the correction of the reading
frame to generate semifunctional dystrophins (Wilton et al.,
1997). The possibility of inducing exon skipping by blocking
recognition sites required for the correct splicing of RNA has ad-
vanced enormously since it was first tested in lymphoblastoid
DMD cells (Pramono et al., 1996) and mdx muscle cells (Dunck-
ley et al., 1998), with promising results in human muscle cultures
and more recently in the mdx mouse model in vivo (Table 1).
The therapeutic use of AOs has advanced enormously: pre-
viously, DNA AOs had been used to downregulate the expres-
sion of specific genes involved in cancer and inflammatory dis-
eases in cell cultures (Zamecnik and Stephenson, 1978) and were
used in an in vitro assay to modulate splicing by targeting splice
sites in a mutated -globin gene associated with -thalassemia
(Dominski and Kole, 1993). These splicing modulation ap-
proaches were later reproduced in human cell lines (HeLa and
NIH 3T3) stably expressing the -globin gene carrying the tha-
lassemic mutation IVS2-654 (Sierakowska et al., 1996). The
method was also tested in human and mouse cell lines stably ex-
pressing mutated genes associated with cystic fibrosis (Friedman
et al., 1999). The modulation of splicing with AOs has also been
shown to be useful in changing the ratio of alternative spliced
transcripts, for example, from an antiapoptotic to a proapoptotic
isoform (Dominski and Kole, 1993; Mercatante et al., 2002).
In most cases, AOs designed to modulate splicing target the
splice donor, acceptor, or branch point sequence. However, exon
skipping can also be induced with AOs targeting exonic splicing
enhancer (ESE) motifs (Aartsma-Rus et al., 2005). These weakly
defined motifs are bound by a subfamily of splicing factors, the
so-called SR proteins, which facilitate splicing by recruitment of
splicing effectors U1 and U2AF to the donor splice site and the
polypyrimidine tract (reviewed in Cartegni et al., 2002). Inter-
estingly, for human DMD exons there is a correlation between
exon “skippability” and the predicted strength of the acceptor
splice site and ESEs but not with the predicted strength of the
donor (5) splice site (Aartsma-Rus and van Ommen, 2007).
However, several years after the first attempts at dystrophin
exon skipping with AOs, there are still no clear rules to guide
investigators in their design, and in mouse and human muscle
cells in vitro there is great variability for different targets and
exons. The consensus sequences at the intron–exon boundaries
that are involved in splice site selection are only poorly con-
served, and the ESEs that are involved in exon definition are
themselves of multiple motifs and their identification is com-
plex. Until these key elements are better understood only length
and target region seem to be important when designing exon-
skipping AOs for the DMD gene (Adams et al., 2007).
As different approaches in AO design lead to different re-
sults, it was clear to us that it was necessary to test a wide range
of AOs to select the best possible sequence for the trial planned
in the United Kingdom. The independent design of AOs by
three research groups (at RH, UWA, and LUMC) guaranteed
as many different approaches to AO design as groups and, while
an independent group (IC) validated the efficacy of the best se-
quences; the final results were eventually cross-checked by ex-
periments performed by each group.
FIG. 6. (A) Muscle explants from a DMD
patient (3–11) were immersed in medium
containing a 400 nM concentration of PMO
AO B30. AO B30 was successful at achiev-
ing the skip in the muscle explant. (B) The
skipped band was analyzed by sequencing
analysis, showing the correct skip.
FIG. 7. Three different PMOs were injected, in a
blinded experiment, into the gastrocnemius muscle
of hDMD mice. Quantification of the PCR products,
using a DNA LabChip, gave the following results:
lane 1 (AO I25, 718), 1.6%; lane 2 (Invert con-
trol), 0%; lane 3 (AO A25, 6387), 5.6%; lane 4
(AO B30, 6695), 22.1%.
A similar strategy was followed when the model in which to
test the AOs was selected: the very nature of this targeted exon
skipping approach makes it impossible to test many of the spe-
cific sequences to be used in humans in healthy volunteers, be-
cause of the potential for disrupting the intact dystrophin open
reading frame, leading to nonfunctional dystrophins. Therefore,
to select the best possible AO to be used in a clinical trial, we
have used several models in an attempt to combine their respec-
tive advantages and limitations to produce a reliable and coher-
ent picture. Human myoblasts allowed us to test the sequences in
a controlled in vitro setting, in which we were able to show the
presence of the correct skipping event both in normal cells and
cells from two DMD patients with different deletions. The RNA
results were further confirmed by the presence of dystrophin pro-
tein in myoblasts from patients carrying these two different dele-
tions treated with both the 2-OMe AOs and PMO AOs. DMD
muscle explants provided the cells with a three-dimensional struc-
ture more similar to the natural environment (McClorey et al.,
2006a) and again we were able to show exon 51 skipping in this
situation. To assess the results in an in vivo model before testing
the AOs in patients, we used a mouse encoding the human DMD
gene. Again, we were able to show the correct exon exclusion.
The comparison has been systematic and the results have
been validated by different laboratories within the collaborat-
ing institutions. The strength of this collaborative approach de-
rives both from the unbiased and blinded analysis of different
sequences and from the multiple independent approaches used,
which took advantage of patient samples with the appropriate
deletions, but also in vivo assessment of efficacy in the hDMD
mouse model. A similar collaborative approach could be used
to validate future target sequences in DMD.
As the results of our study all indicated the superiority of the
AO targeting the sequence (6695) in exon 51, this has been
selected as the reagent that will be used in the first U.K. clini-
cal trial. This trial will evaluate the efficacy of this sequence
on a PMO backbone. Although both 2-OMe and PMO AOs
show promising results in vitro and in vivo, PMOs have the ad-
vantage of having been tested for other purposes in human pa-
tients and are currently in use in clinical trials for restenosis,
cancer, and viral infections (Kipshidze et al., 2005; Nikravesh
et al., 2007). The U.K. trial will be a phase I/IIa study on the
effect of the intramuscular injection of this AO in DMD pa-
tients with relevant deletions. If this first study is successful, a
second clinical trial is planned in which the same AOs will be
administered systemically, as this approach holds promises of
functional benefit for DMD patients.
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